In 2010, Annette McElhiney discovered the Clearity Foundation in her research after she was diagnosed with stage III ovarian cancer.
Five years later, Annette is an ovarian cancer survivor and advocate who continuously shares her story and artwork with the … Read more
By: Laura Shawver
In 1998, Herceptin was approved for women with breast cancer whose tumors have extra copies of the Her2/ERBB2 gene and since that time, there have been more than 25 drugs approved to treat cancers with specific genetic … Read more
The statistics for ovarian cancer are frightening. Whereas early detection tests for breast cancer are relatively commonplace, 75-85% of women with ovarian cancer are diagnosed only at a late stage, when the cancer has spread and prognosis is poor.
More … Read more
Deborah Denehy received chemotherapy directly to her abdomen to treat ovarian cancer, a treatment that remains underused in the United States. Credit Shiho Fukada for The New York Times.
In 2006, the National Cancer Institute took the rare step … Read more
Check out Liz Laats’ amazing speech at Glitter and Glue for Good, not a dry eye in the house.
Thank you to everyone who joined us on March 7th for the inaugaural Glitter & Glue for Good event. More than … Read more
Epithelial ovarian cancer (EOC) is the most common cause of gynecological cancer death in the United States, with an estimated 21,290 new cases and 14,180 deaths estimated for 2015 (ACS 2015). The vast majority of women are diagnosed with advanced … Read more
A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.
Researchers analyzing a database … Read more
Welcome to my Heart to Heart blog designed in the Clearity Portal to provide ovarian cancer survivors with a “cozy space” where we know we will be welcomed and supported.
I’ve been an ovarian cancer survivor for 7 years. I’ve … Read more
By: Cory Bentley, PhD
Bringing new treatments to ovarian cancer patients is very challenging. There are not as many patients diagnosed with this cancer as there are with other cancer types, such as breast, lung and colorectal, so there are … Read more
By Gordon Parry, PhD & Cory Bentley, PhD
The human immune system is very powerful. Successfully harnessing the immune system to destroy tumors, cancer immunotherapy, has been a dream of many oncologists. Cancer immunotherapy has become a reality with … Read more
By: Cory Bentley, PhD
Clearity first reported on drugs inhibiting PARP (Poly-ADP ribose polymerase), an important enzyme for tumor cell proliferation and survival, in its September 2010 patient newsletter. At that time, PARP inhibitors were just entering clinical trials and
… Read moreBy: Evan Friend, MD
The concept of maintenance therapy is based on the idea that by continuing treatment, patients will delay the time to subsequent recurrence or progression of the disease. Whether or not this therapy will lead to improved … Read more
By: Cory Bentley, PhD
Most ovarian cancer patients have become familiar with CA125 blood level monitoring, but trial drug DMUC5754A from Genentech puts a new twist on this familiar blood marker of advanced ovarian cancer. CA125 (cancer antigen 125) also … Read more
By: Cory Bentley, PhD & Teresa Gallagher, PhD
A study presented at the Society of Gynecological Oncology meeting found that most women diagnosed with ovarian cancer are not receiving medical care that meets the guidelines of the National Comprehensive Cancer … Read more
By: Cory Bentley, PhD & Teresa Gallagher, PhD
Ovarian cancer is a very diverse disease on the molecular level. Different tumors have different key molecular players and potentially different Achilles’ heels. Researchers are making real progress in pinpointing key players … Read more
